Impax Laboratories Inc said it would buy a portfolio of generic drugs from Teva Pharmaceutical Industries Ltd and Allergan Plc for about $586 million.
The deal is part of the divestiture process mandated by the U.S. Federal Trade Commission in relation to Teva’s acquisition of Allergan’s generics business for $40.5 billion.
Source: Reuters
Filed Under: Drug Discovery
